2 completed, 2 terminated. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Terminated 2 |
Follow 200 mg linzagolix tablet: new trials by email Literature Review of 200 mg linzagolix tablet trials Research Report on 200 mg linzagolix tablet
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg) - Endometriosis | Phase 3 | Terminated | Kissei Pharmaceutical Co., Ltd. | 30 | 2020-03-23 | 2025-04-02 |
| Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6) 75 mg linzagolix tablet, 200 mg linzagolix tablet, Placebo tablet to match 75 mg linzagolix tablet - Endometriosis | Phase 3 | Completed | Kissei Pharmaceutical Co., Ltd. | 356 | 2020-03-05 | 2025-04-02 |
| Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain. 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg) - Endometriosis | Phase 3 | Completed | Kissei Pharmaceutical Co., Ltd. | 486 | 2019-06-13 | 2025-04-02 |
| A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg) - Endometriosis | Phase 3 | Terminated | Kissei Pharmaceutical Co., Ltd. | 85 | 2019-05-23 | 2025-04-02 |
Constipation (4) · Dysmenorrhea (4) · Dyspareunia (4) · Endometriosis (4)
Kissei Pharmaceutical Co., Ltd. (4)
United States (4) · Austria (2) · Bulgaria (2) · Canada (2) · Czechia (2) · France (2) · Poland (2) · Puerto Rico (2) · Romania (2) · Spain (2) · Ukraine (2) · Hungary (1)